Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy
Cancer Research and Treatment. 2023;55(2):542-550 
Exploring the Influencing Factors of Pathologic Complete Response in Estrogen Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy: A Retrospective Study
. 2021;
Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
BMC Cancer. 2020;20(1):
Utility of 18F-FDG PET/CT for predicting pathologic complete response in Hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
. 2020;
Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
World Journal of Surgical Oncology. 2022;20(1):
Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients
Breast Cancer Research and Treatment. 2020;184(3):999-999
Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Oncology. 2022;100(10):529-535
Validation of Magee equation in predicting response to neoadjuvant chemotherapy in breast cancer patients with hormone receptor positive and HER2 negative
The Breast. 2019;44:S73
Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer – Moving beyond pathological complete response
The Breast. 2014;23(2):188-192
Estrogen Receptor-negative/progesterone Receptor-positive and Her-2 Negative Breast Cancer Might No Longer Be Classified as Hormone Receptor Positive Breast Cancer
. 2020;